Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infliximab for Dolichoectactic Vertebrobasilar Aneurysms
NCT02638701Phase 2Recruiting
- Sponsor
- University of California, San Francisco
- Start
- Oct 2024
- Primary completion
- Jun 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of infliximab in Vertebrobasilar aneurysm (VBAA), sponsored by University of California, San Francisco. Primary endpoint: Reduction in aneurysm volume at 12 months. Started Oct 2024; status: recruiting.
02
Drugs
infliximab
03
Conditions
Vertebrobasilar aneurysm (VBAA)
Beyond the preview
Go deeper on NCT02638701.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02638701.